Bausch Health Companies Stock News

As Club members know, we're looking to these IPOs as a means of unlocking value by separating the three core operating business.

Bausch Health is spinning off both Solta Medial, its skin-care business, and Bausch + Lomb into separate, publicly traded companies.

Bausch Health Canada, part of Bausch Health (BHC), announced the availability of Trulance for treating irritable bowel syndrome with constipation in adults, through

WASHINGTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- The Global Acute Repetitive Seizures Market size is expected to reach over USD 998.1 Million by 2028, exhibiting a CAGR of 47.5% during the forecast period. Market Synopsis High clinical needs for patients which are unmet, coupled with availability of advanced product pipeline and caregivers, are some of the key factors likely to drive market growth for Acute Repetitive Seizures. Drug therapy is persuasive for most of the patients who are suffering from cluster seizures. There are a substantial number of treatment restraints and unmet medical needs like, adverse reactions, drug-induced seizures, and lack of antiepileptogenic agents which can prevent the seizures development and its comorbidities, states Vantage Market Research, in a report, titled " Acute Repetitive Seizures Market by Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Bausch Health is unlocking value by spinning off into 3 separate companies. The partial Bausch and Lomb & Solta spinoff proceeds will be used to pay down debt.

Bausch Health Companies (BHC) launches offering of $1B principal mount of new senior secured notes due 2027 in the private placement deal; terms yet to be determined. Closing of

Gamblers who play craps are familiar with the “don't pass” bet. Players who put their money on this bet are known as “wrong players” since they are usually betting against the shooter, who is

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

In the latest trading session, Bausch Health (BHC) closed at $25.06, marking a +0.56% move from the previous day.

Bausch Health Companies (BHC) announced the appointment of Dr

6 Top Biotech Ideas For 2022

Bausch Health is seeking to refinance its existing credit agreement in anticipation of its planned IPO of Bausch + Lomb.

Bausch Health Companies Inc.'s ( BHC , Financial) plans to split into three public companies is pretty much a done deal, CEO Joseph Papa said at last week's J.P. Morgan Healthcare Conference.

Bausch Health Companies ( BHC , Financial) ( TSX:BHC , Financial), which is dual listed in the U.S. and Canada, is planning on splitting into three companies this year - Bausch+Lomb, Solta Medical and